



Randomized Comparison of Transcatheter Edge-to-Edge Repair For Degenerative Mitral Regurgitation in Prohibitive Surgical Risk Patients

Multicenter, Randomized, Non-Inferiority Trial

OBJECTIVE: To evaluate the safety and efficacy of the PASCAL system vs. the MitraClip system for transcatheter treatment of severe symptomatic degenerative mitral regurgitation.



PRIMARY ENDPOINT

Safety endpoint, a composite major adverse event rate, occurred in 3.4% in PASCAL vs. 4.8% in MitraClip, met non-inferiority.

Efficacy endpoint, MR ≤2+, for PASCAL vs. MitraClip: 96.5% vs. 96.8%, met non-inferiority.

CONCLUSION

Among patients with severe degenerative mitral regurgitation with prohibitive surgical risk, the CLASP IID trial demonstrated safety and effectiveness of the PASCAL system and was non-inferior to the MitraClip system.

Lim DS, Smith RL, Gillam LD., et al. Randomized Comparison of Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation in Prohibitive Surgical Risk Patients *J Am Coll Cardiol Intv* 2022; Sep 17; [Epub Ahead of Print].

Developed and reviewed by Neil Keshvani, MD; Dharam J. Kumbhani, MD, SM, FACC; and Deepak L. Bhatt, MD, MPH, FACC.